Abstracts
Objective Inpatients with high risk of venous thromboembolism (VTE) usually face serious threats to their health and economic conditions. Many studies using machine learning (ML) models to predict VTE risk neglected an important statistical phenomenon, ‘fuzzy feature’, and achieved inferior results. Considering the effect of ‘fuzzy feature’, our study aims to develop a VTE risk assessment model suitable for Chinese medical inpatients.
Materials and Methods Inpatients in the medical department of Peking Union Medical College Hospital (PUMCH) from January 2014 to June 2016 were collected. A new ML VTE risk assessment model was built through population splitting. First patients were classified into different groups based on values of VTE risk factors, then trustless groups were filtered out, and finally ML models were built on training data in unit of groups. Predictive performances of our method, five traditional ML models, and the Padua model were compared.
Results The ‘fuzzy feature’ was verified on the whole dataset. Compared with the Padua model, the proposed model showed higher sensitivities and specificities on training data, and higher specificities and similar sensitivities on test data. Standard deviations of predictive validity of five ML models were larger than the proposed model.
Discussion The proposed model was the only one which showed advantages on both sensitivity and specificity over Padua model. Its robustness was better than traditional ML models.
Conclusion This study built a population-split-based ML model of VTE for Chinese medical inpatients and it may help clinicians stratify VTE risk and guide prevention more efficiently.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work is supported by the Chinese Academy of Medical Sciences Fundamental Research Funds (2019XK320044)
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the Ethics Committee of PUMCH in Chinese Academy of Medical Sciences (reference number for ethics approval: B164)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the corresponding author